Marevan (Warfarin Sodium)

Warfarin sodium blocks vitamin K epoxide reductase, an enzyme needed to recycle vitamin K. Without active vitamin K, the liver cannot produce functional clotting factors II, VII, IX and X, leading to reduced blood clot formation and prolonged clotting time.

The dose of Marevan is individualized by the prescribing clinician. Dosage is adjusted based on regular monitoring of the International Normalized Ratio (INR) to keep anticoagulation within a therapeutic range specific to the patient’s condition.

Warfarin’s pregnancy category is unknown, and it is generally avoided during pregnancy because of potential fetal harm. Use while breastfeeding is also not recommended unless the benefits clearly outweigh the risks, and should be discussed with a healthcare professional.

To order Marevan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Marevan (warfarin) is a vitamin K antagonist that requires INR monitoring and has many drug and food interactions. Direct oral anticoagulants such as apixaban or rivaroxaban have more predictable pharmacokinetics, fewer dietary restrictions, and do not require routine lab monitoring, but may be more costly and have different renal considerations.

Marevan tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Marevan is taken orally as a tablet, usually once daily. It can be swallowed with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

The most serious risks associated with Marevan include major bleeding events such as gastrointestinal hemorrhage or intracranial bleed, skin necrosis that can appear early in therapy, and rare allergic reactions like anaphylaxis. Prompt medical attention is required if any of these occur.

Marevan is contraindicated in patients with active major bleeding, recent intracranial hemorrhage, severe uncontrolled hypertension, known hypersensitivity to warfarin, or those who are pregnant unless the benefits outweigh the risks. Clinicians should also assess liver disease, renal impairment and other comorbidities before prescribing.